(5R)-5-Hydroxytriptolide (LLDT-8) inhibits osteoclastogenesis via RANKL/RANK/OPG signaling pathway

BACKGROUND: The aim of this study was to investigate the regulative activity of (5R)-5-hydroxytriptolide (LLDT-8) on receptor activator of nuclear factor κ-B ligand (RANKL)/receptor activator of nuclear factor κ-B (RANK)/Osteoprotegerin (OPG) system in rheumatoid arthritis (RA) and its anti-osteocla...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Complement Altern Med
Autors principals: Shen, Yi, Jiang, Ting, Wang, Rongsheng, He, Shijun, Guo, Mengru, Zuo, Jianping, He, Dongyi
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2015
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4379732/
https://ncbi.nlm.nih.gov/pubmed/25887296
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12906-015-0566-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars